Ruodi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruodi Yang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Juntong Liu
Teaching and Experimental Center Liaoning University of Traditional Chinese Medicine Shenyang China
2 shared publications - Yan Shi
School of Marxism Liaoning University of Traditional Chinese Medicine Shenyang China
2 shared publications - Ying Zhou
First Clinical School Liaoning University of Traditional Chinese Medicine Shenyang China
2 shared publications - Yufeng Yang
Liaoning University of Traditional Chinese Medicine, Shenyang, China
2 shared publications Jiaxin Li
Department of Basic Medical Sciences Liaoning University of Traditional Chinese Medicine Shenyang China
1 shared publication- Qing-Feng Wang
Liaoning University of Traditional Chinese Medicine
1 shared publication
Latest Publications
- 18 October 2026
- Published by Wiley in Medicinal Research Reviews
Targeting the Gut Microbiota‐Metabolism Axis: Novel Pharmacological Mechanisms and Translational Application Strategies for Oral Antidiabetic Drugs
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic metabolic disease worldwide, and the clinical prevention and control situation is severe. Although the various antidiabetic drugs currently in clinical use can lower blood glucose levels through different mechanisms, there are significant differences in efficacy among individuals. Existing evidence suggests that differences in gut microbiota (GM) composition and metabolic function may be one of the key factors contributing to the heterogeneity in drug efficacy. Based on this, this review describes the physiological and pathological mechanisms of the GM‐metabolism axis and systematically reviews the modulatory effects of different classes of antidiabetic drugs on this axis and their underlying mechanisms. Available studies suggest that metformin, α‐glucosidase inhibitors, dipeptidyl peptidase‐4 inhibitors (DPP‐4i), sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), thiazolidinediones (TZDs), and oral glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may differentially affect GM composition and/or microbial metabolites, including short‐chain fatty acids (SCFAs), branched‐chain amino acids (BCAAs), and bile acids. These alterations may be associated with glucose homeostasis and insulin resistance through pathways involving GPR41/43, HDACs, AMPK, mTORC1/S6K1, FXR‐FGF15/19, and TGR5‐GLP‐1 signaling. By integrating clinical and mechanistic evidence, this review highlights the potential contribution of the GM‐metabolism axis to the glucose‐lowering effects of antidiabetic drugs. However, the quantity and confidence of evidence vary substantially across drug classes, and causal and clinical relevance requires further validation. These findings provide a basis for future research on personalized interventions for T2DM characterized by SCFA‐producing bacterial deficiency, BCAA overload, or dysregulated bile acid metabolism.
- 18 October 2026
- Published by Wiley in Medicinal Research Reviews
Targeting the Gut Microbiota‐Metabolism Axis: Novel Pharmacological Mechanisms and Translational Application Strategies for Oral Antidiabetic Drugs
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic metabolic disease worldwide, and the clinical prevention and control situation is severe. Although the various antidiabetic drugs currently in clinical use can lower blood glucose levels through different mechanisms, there are significant differences in efficacy among individuals. Existing evidence suggests that differences in gut microbiota (GM) composition and metabolic function may be one of the key factors contributing to the heterogeneity in drug efficacy. Based on this, this review describes the physiological and pathological mechanisms of the GM‐metabolism axis and systematically reviews the modulatory effects of different classes of antidiabetic drugs on this axis and their underlying mechanisms. Available studies suggest that metformin, α‐glucosidase inhibitors, dipeptidyl peptidase‐4 inhibitors (DPP‐4i), sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), thiazolidinediones (TZDs), and oral glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may differentially affect GM composition and/or microbial metabolites, including short‐chain fatty acids (SCFAs), branched‐chain amino acids (BCAAs), and bile acids. These alterations may be associated with glucose homeostasis and insulin resistance through pathways involving GPR41/43, HDACs, AMPK, mTORC1/S6K1, FXR‐FGF15/19, and TGR5‐GLP‐1 signaling. By integrating clinical and mechanistic evidence, this review highlights the potential contribution of the GM‐metabolism axis to the glucose‐lowering effects of antidiabetic drugs. However, the quantity and confidence of evidence vary substantially across drug classes, and causal and clinical relevance requires further validation. These findings provide a basis for future research on personalized interventions for T2DM characterized by SCFA‐producing bacterial deficiency, BCAA overload, or dysregulated bile acid metabolism.
- 26 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (01) , 35-63
Regulation of Traditional Chinese Medicine Gut Microbiota Short-Chain Fatty Acid Axis in Type 2 Diabetes Management: A Review
Type 2 diabetes mellitus (T2DM), a globally prevalent chronic metabolic disorder, imposes a significant worldwide public health burden. As a vital “microbial organ” within the human body, the balance of the gut microbiota (GM) structure and function is crucial for maintaining host metabolic health. Short-chain fatty acids (SCFAs), the metabolic products of GM, serve as key signaling molecules that play central roles in maintaining intestinal homeostasis, regulating systemic energy metabolism, and improving insulin sensitivity. Dysregulation of the “GM-SCFA axis” has emerged as a core pathological mechanism in the onset and progression of T2DM. Traditional Chinese Medicine (TCM) possesses unique advantages in T2DM treatment through its “holistic regulation and multi-targeted intervention,” which enables precise modulation of the GM-SCFA axis. This paper provides a systematic review of the pathological mechanisms by which dysregulation of the GM-SCFA axis induces T2DM, and specifically covers energy metabolism disorders, insulin resistance, intestinal barrier impairment, chronic low-grade inflammatory activation, abnormal bile acid metabolism regulation, and disrupted gut-pancreatic axis and gut-brain axis signaling. Using keywords such as TCM, GM, SCFAs, and T2DM, we conducted an extensive literature search across databases including PubMed, Google Scholar, and Web of Science for publications from the past decade. This systematic review examines the application of TCM in regulating the “GM-SCFA axis” from multiple perspectives: Chinese herbal compounds (e.g., Zuogui Jiangtang Qinggan Formula, Gegen Qinlian Decoction), Chinese patent medicines (e.g., Shouhui Tongbian Capsules, Compound Danshen Dripping Pills), single-herb Chinese medicines (e.g., Edgeworthia gardneri, Alpinia oxyphylla), single-component compounds from TCM (e.g., Cyclocarya paliurus polysaccharide, Achyranthes bidentata polysaccharide water-soluble 1), and other TCM therapies (e.g., tuina, acupuncture). This study aims to systematically explore the mechanisms by which dysregulation of the “GM-SCFA axis” induces T2DM while providing novel therapeutic strategies for T2DM prevention and treatment using TCM. It also seeks to establish scientific foundations for developing novel TCM intervention strategies targeting the “GM-SCFA axis” in T2DM management.
- 26 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (01) , 35-63
Regulation of Traditional Chinese Medicine Gut Microbiota Short-Chain Fatty Acid Axis in Type 2 Diabetes Management: A Review
Type 2 diabetes mellitus (T2DM), a globally prevalent chronic metabolic disorder, imposes a significant worldwide public health burden. As a vital “microbial organ” within the human body, the balance of the gut microbiota (GM) structure and function is crucial for maintaining host metabolic health. Short-chain fatty acids (SCFAs), the metabolic products of GM, serve as key signaling molecules that play central roles in maintaining intestinal homeostasis, regulating systemic energy metabolism, and improving insulin sensitivity. Dysregulation of the “GM-SCFA axis” has emerged as a core pathological mechanism in the onset and progression of T2DM. Traditional Chinese Medicine (TCM) possesses unique advantages in T2DM treatment through its “holistic regulation and multi-targeted intervention,” which enables precise modulation of the GM-SCFA axis. This paper provides a systematic review of the pathological mechanisms by which dysregulation of the GM-SCFA axis induces T2DM, and specifically covers energy metabolism disorders, insulin resistance, intestinal barrier impairment, chronic low-grade inflammatory activation, abnormal bile acid metabolism regulation, and disrupted gut-pancreatic axis and gut-brain axis signaling. Using keywords such as TCM, GM, SCFAs, and T2DM, we conducted an extensive literature search across databases including PubMed, Google Scholar, and Web of Science for publications from the past decade. This systematic review examines the application of TCM in regulating the “GM-SCFA axis” from multiple perspectives: Chinese herbal compounds (e.g., Zuogui Jiangtang Qinggan Formula, Gegen Qinlian Decoction), Chinese patent medicines (e.g., Shouhui Tongbian Capsules, Compound Danshen Dripping Pills), single-herb Chinese medicines (e.g., Edgeworthia gardneri, Alpinia oxyphylla), single-component compounds from TCM (e.g., Cyclocarya paliurus polysaccharide, Achyranthes bidentata polysaccharide water-soluble 1), and other TCM therapies (e.g., tuina, acupuncture). This study aims to systematically explore the mechanisms by which dysregulation of the “GM-SCFA axis” induces T2DM while providing novel therapeutic strategies for T2DM prevention and treatment using TCM. It also seeks to establish scientific foundations for developing novel TCM intervention strategies targeting the “GM-SCFA axis” in T2DM management.